Jorge Cortes

Jorge Cortes is a hematologist at the University of Texas , MD Anderson Cancer Center.[12]He specializes in medicine.[3]He is a member of Department of Leukemia.[4]

Jorge Eduardo Cortes, MD Dr. Cortes is a Deputy Chair and Professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston Texas where he directs the CML Program.[5]He is chief editor of Hematological Malignancies Reports and Clinical Leukemia and serves in the Editorial Board of the Journal of Clinical Oncology, Leukemia, Clinical Cancer Research, Leukemia and Lymphoma and the American Journal of Hematology.[5]He led the development of the second generation tyrosine kinase inhibitor bosutinib and the third generation ponatinib, which are widely used today.[6]He has served as a member of the Medical Advisory Board of the National CML Society since 2010, and a member of the Board of Directors of the International CML Foundation since 2009.[6]He also is president and founder of the Latin American Leukemia Net, based in Mexico City, an organization that focuses on patient education in Latin America.[6]He has authored several books and book chapters in prestigious publications such as Cancer Medicine and Harrison's Principles of Internal Medicine.[3]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Jorge Cortes on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Department of Leukemia


  • 1


  • 292


  • 118


Recent events

U.S. FDA Approves DAURISMO™ (glasdegib) ...

In adults, however, abnormal activation of this pathway is thought to contribute to the development and persistence of cancer stem cells. "The randomized Phase 2 study, which formed the basis for today's approval, included patients with cardiac disease or mild to moderate kidney disease, who are often excluded from clinical trials," said Jorge Cortes, M.D., deputy chair and professor of medicine in the Department of Leukemia, University of Texas, MD Anderson Cancer Center. Pfizer's commitment to hematologic malignancies began in 2012 with the approval of our treatment for chronic myeloid leukemia . Today, Pfizer Oncology has an industry-leading portfolio of 14 approved cancer medicines across 22 indications, including breast, prostate, kidney, lung and hematology.[789]


Event Date